Nahdi Medical Company
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nahdi Medical Company's yearly results (2022–2025), compared with Healthcare companies in Saudi Arabia. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 19% in 3 years, but profit fell: SAR 4 less profit per SAR 100 of extra sales. Lower than 88% of Healthcare companies in Saudi Arabia.
- Cash Locked Ratio: For every SAR 100 of sales, SAR 11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against SAR 8 tied up three years earlier. Less money tied up than 88% of Healthcare companies in Saudi Arabia.
Where SAR 100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
SAR 155Over the last 3 years, every SAR 100 of reported profit came with SAR 155 of operating cash.
Higher than 71% of Healthcare companies in Saudi Arabia.
Self-Funding Ratio
3.3×Over the last 3 years its own operating cash covered its investment spending (capex) 3.3 times.
Higher than 62% of Healthcare companies in Saudi Arabia.
Cash Locked Ratio
SAR 11For every SAR 100 of sales, SAR 11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against SAR 8 tied up three years earlier.
Less money tied up than 88% of Healthcare companies in Saudi Arabia.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Less steady than 67% of Healthcare companies in Saudi Arabia.
Growth Efficiency Ratio
−SAR 4Sales grew 19% in 3 years, but profit fell: SAR 4 less profit per SAR 100 of extra sales.
Lower than 88% of Healthcare companies in Saudi Arabia.
Asset Productivity Ratio
+19% / +35%In 3 years sales changed by +19% while total assets changed by +35%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.7×Debt due within a year is covered 2.7 times by its yearly operating cash.
Higher than 54% of Healthcare companies in Saudi Arabia.
Cash Cushion Ratio
−11%Debt, after subtracting cash, equals 11% of its market value (net debt).
Higher than 54% of Healthcare companies in Saudi Arabia.
Tangible Assets Ratio
99%Of every SAR 100 the company owns, SAR 99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 50% of Healthcare companies in Saudi Arabia.
Tangible Net Worth Ratio
98%Of every SAR 100 of net worth, SAR 98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 50% of Healthcare companies in Saudi Arabia.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Nahdi Medical Company owes SAR 0.63 for every SAR 1 it owns. Net profit rose 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Compared with Healthcare companies in Saudi Arabia · latest annual results Dec 2025.
P/E ratio
14.4Investors pay SAR 14.4 for every SAR 1 of Nahdi Medical Company's yearly profit, lower than 71% of Healthcare companies in Saudi Arabia.
P/B ratio
4.51The share price is 4.51 times Nahdi Medical Company's book value per share, higher than 79% of Healthcare companies in Saudi Arabia.
Market cap
SAR 11.3 BThe total market value of all of Nahdi Medical Company's shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in Saudi Arabia. PosiCap size class: Meso Cap.
Net worth (book value)
SAR 2.5 BWhat Nahdi Medical Company would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
SAR 19.32Net worth divided by the number of shares. The share price of SAR 87.10 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
30.3%Nahdi Medical Company earned 30.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in Saudi Arabia.
Owes vs Owns
0.63×Nahdi Medical Company owes SAR 0.63 for every SAR 1 it owns (moderate), higher than 71% of Healthcare companies in Saudi Arabia.
Dividend yield
6.34%Nahdi Medical Company pays 6.34% of its share price as dividends a year, higher than 88% of dividend-paying Healthcare companies in Saudi Arabia.
Revenue growth
+8%Revenue rose 8% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Profit growth
+1%Net profit rose 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit margin
8.1%Nahdi Medical Company keeps SAR 8 of every SAR 100 of revenue as net profit.
Cash quality
1.4×Cash from Nahdi Medical Company's business was 1.4× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
10.4×Nahdi Medical Company's operating profit covered its interest costs 10.4 times in the year to Dec 2025.
Cash vs debt
Net debtNahdi Medical Company had SAR 1.2 B more debt than cash (net debt) at Dec 2025.
Questions
What is Nahdi Medical Company's P/E ratio?
Investors pay SAR 14.4 for every SAR 1 of Nahdi Medical Company's yearly profit, lower than 71% of Healthcare companies in Saudi Arabia.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nahdi Medical Company: SAR 11.3 B ÷ SAR 2.5 B (30 Jun 2026) = 4.5.
What is Nahdi Medical Company's return on equity?
Nahdi Medical Company earned 30.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in Saudi Arabia.
How much does Nahdi Medical Company owe compared with what it owns?
Nahdi Medical Company owes SAR 0.63 for every SAR 1 it owns (moderate), higher than 71% of Healthcare companies in Saudi Arabia.
Does Nahdi Medical Company pay a dividend?
Yes. Nahdi Medical Company pays 6.34% of its share price as dividends a year, higher than 88% of dividend-paying Healthcare companies in Saudi Arabia.
Is Nahdi Medical Company's revenue growing?
Revenue rose 8% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.